Additionally, neurexin 2α, GluA4-containing glutamate receptor, and neuroligin 1, all proteins essential for long-term potentiation processes, are all significantly lower in NDEVs of patients 6–11 years prior to AD diagnosis and, along with neuronal pentraxin 2, are all downregulated in NDEVs of AD patients [73]. This evidence concerns the gene GRIA4 and Alzheimer disease.